Shares of Gaxos.ai Inc (NASDAQ: GXAI) traded lower Tuesday afternoon, dropping 22.94% to 84 cents, despite the Roseland, New Jersey-based technology company reporting significant top-line expansion for the first quarter of 2026. The stock hit a new 52-week low as investors digested the company’s post-divestiture operational strategy, which sees management reallocating resources toward business units with proven commercial traction following the completed sale of its gaming assets.

Q1 Revenue Surges on Health and AI Segments

Gaxos.ai reported first-quarter 2026 revenue of approximately $1.81 million, marking a steep increase from the around $24,000 recorded in first-quarter 2025. This substantial growth underscores the financial impact of the company’s strategic pivot away from its former gaming operations.

The revenue composition highlights the dominance of its two core remaining segments:

RNK Health contributed $1.25 million, accounting for the majority of the top-line performance, while Gaxos Labs generated $563,000 primarily through application subscriptions.

Strategic Refocus on Core Operations

Following the divestiture of its gaming assets, Gaxos.ai announced it is concentrating primarily on its portfolio of consumer and enterprise AI applications under Gaxos Labs, alongside RNK Health’s personalized health and wellness product line. Management expects this streamlined structure to enhance customer acquisition efficiency and improve operational focus.

What the Numbers Show

The divergence between the strong fundamental performance—evidenced by a near-7,000% year-over-year revenue increase—and the sharp 22.94% decline in share price suggests market skepticism regarding the sustainability of the new model or broader sentiment toward small-cap tech stocks. While the absolute revenue base remains modest at $1.81 million, the clear separation of revenue streams between health products and AI applications provides a transparent view of where the company’s current commercial traction lies.